Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Drug Discov. 2004 Dec;3(12):1011-22.

Development of TGF-beta signalling inhibitors for cancer therapy.

Author information

1
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA. yingling_jonathan_m@lilly.com

Abstract

The transforming growth factor-beta (TGF-beta) superfamily of ligands has a pivotal role in the regulation of a wide variety of physiological processes from development to pathogenesis. Since the discovery of the prototypic member, TGF-beta, almost 20 years ago, there have been tremendous advances in our understanding of the complex biology of this superfamily. Deregulation of TGF-beta has been implicated in the pathogenesis of a variety of diseases, including cancer and fibrosis. Here we present the rationale for evaluating TGF-beta signalling inhibitors as cancer therapeutics, the structures of small-molecule inhibitors that are in development and the targeted drug discovery model that is being applied to their development.

PMID:
15573100
DOI:
10.1038/nrd1580
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center